[Skip to Content]
[Skip to Content Landing]
Research Letter
July 2016

Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014

Author Affiliations
  • 1Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
  • 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
JAMA Oncol. 2016;2(7):960-961. doi:10.1001/jamaoncol.2016.0648

Prescription drug pricing and changes in prices for existing drugs have been under intense scrutiny recently.1 For anticancer medications, high drug prices have the potential to affect access and adherence to therapies and increase financial burden for patients.25 Given the rapidly evolving drug pricing landscape, it is important to evaluate recent pricing for anticancer medications. This study’s objectives were to estimate changes in reimbursements for orally administered anticancer drugs paid by commercial health plans from 2000 through 2014, focusing on reimbursements during the year of product launch and changes in reimbursements over time.

First Page Preview View Large
First page PDF preview
First page PDF preview